Education
About Us
Working with TipRanks
Follow Us
Rein Therapeutics (RNTX)
NASDAQ:RNTX
RNTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.04 - $4.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)192.09K
Market Cap
$27.79M
Enterprise Value$73.15M
Total Cash (Recent Filing)$5.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Nov 14, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding23,547,428
10 Day Avg. Volume321,650
30 Day Avg. Volume192,087
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap2.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-73.15K
Enterprise Value/Ebitda-5.86
Forecast
1Y Price Target
$10.00Price Target Upside747.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalThe likelihood of a lift of the U.S. pause is now the most likely path, which could speed up overall trial enrollment.
Stock Price TargetThe disconnect between the current $1.21 price and the $10 price target is seen as a positive for the stock.
Bears Say
Clinical Trial DelaysRNTX’s Q2 update was disappointing, as the company is still waiting for a meeting with the FDA regarding the clinical hold of the Phase 2 RENEW trial which is expected to delay the trial by up to 10 months.
Financial SustainabilityCash of $5.7MM, plus the recent Yorkville Capital transaction, can fund operations only through Q4:2025, raising skepticism about the company's ability to generate the needed funds in a competitive IPF space.
Funding ConcernsThere is concern about the lack of sufficient funding to restart its Phase 2 trial in the US and the ability to raise the approximately $40MM needed to run the study.
Rein Therapeutics News
RNTX FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was $1.04 and its highest was $4.40 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is $27.79M.
When is Rein Therapeutics’s upcoming earnings report date?
Rein Therapeutics’s upcoming earnings report date is Nov 14, 2025 which is in 45 days.
How were Rein Therapeutics’s earnings last quarter?
Rein Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.282 earnings per share for the quarter, missing the consensus estimate of -$0.22 by -$0.062.
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate is -0.24.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 23,547,428 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Rein Therapeutics reported an EPS of -$0.282 in its last earnings report, missing expectations of -$0.22. Following the earnings report the stock price went down -1.695%.
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in RNTX
Rein Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (747.46% Upside)
$10.00 (747.46% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.13%
12-Months-Change
Fundamentals
Return on Equity
-79.38%
Trailing 12-Months
Asset Growth
-47.46%
Trailing 12-Months
Company Description
Rein Therapeutics
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
RNTX Stock 12 Month Forecast
Average Price Target
$10.00
▲(747.46% Upside)
Technical Analysis
Sonnet BioTherapeutics Holdings
―
Kezar Life Sciences
―
Vivos Therapeutics
―
OnKure Therapeutics
―
Rani Therapeutics Holdings
―
Ownership Overview
1.95% Insiders
4.46% Mutual Funds
22.38% Other Institutional Investors
67.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---